DexCom, Inc.
DXCM
NASDAQ·Healthcare·Medical - Devices·Mkt cap $33.2B
$87.90
▼ -2.02%
P/E
34.61
Mkt Cap
$33.2B
52-Wk Range
$54.11–$92.59
52-Week Range
$54.11 - $92.59
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 12.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced proprietary CGM technology
- Strong intellectual property portfolio
- Strategic technology partnerships
- User-friendly digital health ecosystem
Bear Case
2 risks
- Average volatility.
- Significant premium - growth priced in
Growth
Stable outlook
Global diabetes prevalence increase
Value
Significant premium - growth priced in
Momentum
Strong
+14.7% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying DXCM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 30, 2026
Reported EPS of $0.70 vs $0.61 consensus (+14.6% surprise). Revenue of $1.3B vs $1.3B expected (+1.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+14.6%
Revenue trend · last 8Q
—
+8%
+12%
+15%
+22%
+13%
+15%
+13%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$994.2M
$1.1B
$1.0B
$1.2B
$1.2B
$1.3B
$1.2B
$1.3B
Margins · last 8Q
Gross
63.4%
Operating
24.3%
Profit
19.0%
Wall Street consensus
10 analysts · 90% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
90%
Hold
0%
Sell
10%
Median Price Target
—
Latest: Benchmark · Jul 31, 2026
vs Industry
How DXCM stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related